Sight Sciences Q2 2024 Earnings Report $2.53 -0.23 (-8.33%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Sight Sciences EPS ResultsActual EPS-$0.25Consensus EPS -$0.31Beat/MissBeat by +$0.06One Year Ago EPS-$0.30Sight Sciences Revenue ResultsActual Revenue$21.37 millionExpected Revenue$21.32 millionBeat/MissBeat by +$50.00 thousandYoY Revenue GrowthN/ASight Sciences Announcement DetailsQuarterQ2 2024Date8/1/2024TimeAfter Market ClosesSGHT Upcoming EarningsSight Sciences will be holding an earnings conference call on Wednesday, March 5 at 4:30 PM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseSGHT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Sight Sciences Earnings HeadlinesBrokerages Set Sight Sciences, Inc. (NASDAQ:SGHT) Price Target at $4.68February 22 at 1:11 AM | americanbankingnews.comSight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025February 19 at 4:05 PM | globenewswire.comCritical ‘Buy Now’ Alert on My Favorite Stock!My absolute favorite stock just hit a critical "buy now" trigger price.February 22, 2025 | Behind the Markets (Ad)Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access DayFebruary 13, 2025 | finance.yahoo.comSight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access DayFebruary 13, 2025 | globenewswire.comSight Sciences stock hits 52-week low at $2.54 amid market challengesFebruary 13, 2025 | msn.comSee More Sight Sciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sight Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sight Sciences and other key companies, straight to your email. Email Address About Sight SciencesSight Sciences (NASDAQ:SGHT), an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.View Sight Sciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
